Oncotelic Therapeutics (OTLC) awards 250 RSUs conditioned on uplisting
Rhea-AI Filing Summary
KING STEVEN W reported acquisition or exercise transactions in this Form 4 filing.
Oncotelic Therapeutics granted director Steven W. King 250 restricted stock units (RSUs) on July 10, 2026 at $0.00 per unit. Each RSU is subject to performance and time-based vesting and represents a contingent right to one share of Series A Convertible Preferred Stock, with each such share convertible into 1,000 common shares. The RSUs vest only if the company uplists its common stock to a national securities exchange on or before June 30, 2027 (or a later Board-approved date) and he remains in service for six months after any such uplisting; following this grant he holds 250 RSUs directly.
Positive
- None.
Negative
- None.
Insider Trade Summary
1 transaction reported
Mixed
1 txn
Insider
KING STEVEN W
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Restricted stock Units F1, F2 | 250 | $0.00 | $0.00 |
Holdings After Transaction:
Restricted stock Units — 250 shares (Direct)
Footnotes (2)
- F1. On July 10, 2026, the reporting person was granted 250 restricted stock units ("RSUs"), subject to performance and time-based vesting. On vesting each RSU will immediately be settled by delivery of, and each RSU represents the contingent right to receive, one share of the issuer's Series A Convertible Preferred Stock, par value $0.01. Each share of Series A Convertible Preferred Stock, in turn, is convertible into 1,000 shares of the issuer's common stock, par value $0.01 per share.
- F2. The RSU's will vest upon (a) achievement of an uplisting of the issuer's common stock to a national securities exchange on or before June 30, 2027 (or such later date as the Board of Directors may approve), subject to the reporting person's continued service for a period of six months following the uplisting.
Key Figures
Restricted stock units granted: 250 units
Grant price per RSU: $0.00 per unit
RSUs held after transaction: 250 units
+4 more
7 metrics
Restricted stock units granted
250 units
Equity award granted to director Steven W. King on July 10, 2026
Grant price per RSU
$0.00 per unit
Reported transaction price per restricted stock unit
RSUs held after transaction
250 units
Total restricted stock units held directly by Steven W. King following the grant
RSU underlying security
1 Series A preferred share per RSU
Each RSU settles in one share of Series A Convertible Preferred Stock upon vesting
Conversion ratio to common stock
1,000 common shares per preferred share
Each Series A Convertible Preferred share is convertible into 1,000 common shares
Par value of Series A Preferred
$0.01 per share
Par value of the Series A Convertible Preferred Stock underlying the RSUs
Uplisting vesting deadline
June 30, 2027
Deadline to achieve uplisting for RSUs to vest, subject to Board-approved extension
Key Terms
restricted stock units, Series A Convertible Preferred Stock, performance and time-based vesting, uplisting, +1 more
5 terms
restricted stock units financial
"the reporting person was granted 250 restricted stock units ("RSUs"), subject to performance"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
Series A Convertible Preferred Stock financial
"one share of the issuer's Series A Convertible Preferred Stock, par value $0.01"
Series A convertible preferred stock is a class of shares sold in an early funding round that gives investors a mix of protection and upside: it pays a priority claim over common shares if the company is sold or closes, but can be converted into ordinary shares to share in future growth. Think of it like a hybrid between a safer stake and a ticket to ownership; it matters to investors because it affects who controls the company, how future gains are split, and how much their investment is protected from downside.
performance and time-based vesting financial
"250 restricted stock units ("RSUs"), subject to performance and time-based vesting"
uplisting market
"will vest upon (a) achievement of an uplisting of the issuer's common stock"
Uplisting occurs when a company's stock moves from a less regulated, smaller exchange to a more established and widely recognized one. This transition can make the stock more accessible and attractive to a broader range of investors, potentially increasing its value and trading volume. For investors, uplisting often signals growth and stability, which can influence confidence and trading decisions.
national securities exchange market
"uplisting of the issuer's common stock to a national securities exchange on or before June 30, 2027"
A national securities exchange is a regulated marketplace where buyers and sellers trade stocks, bonds and other securities and where companies meet requirements to have their shares available to the public. It matters to investors because the exchange enforces rules, provides transparent prices and a steady flow of buyers and sellers—like a supervised marketplace that helps ensure fair pricing, easier buying and selling, and basic investor protections.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What insider transaction did Oncotelic Therapeutics (OTLC) report for Steven W. King?
On July 10, 2026, Oncotelic Therapeutics granted director Steven W. King 250 restricted stock units at $0.00 per unit. These RSUs are equity compensation tied to vesting and potential conversion into Series A Convertible Preferred Stock.
What are the vesting conditions for the 250 OTLC RSUs granted to Steven W. King?
The 250 RSUs vest only upon an uplisting of OTLC’s common stock to a national securities exchange on or before June 30, 2027 (or a later Board-approved date). Vesting also requires King’s continued service for six months following any such uplisting.
How can Steven W. King’s OTLC RSUs ultimately convert into common stock?
Each RSU represents a contingent right to receive one share of Series A Convertible Preferred Stock. Each preferred share is, in turn, convertible into 1,000 shares of Oncotelic’s common stock, subject to the RSUs first meeting their vesting conditions.
How many OTLC RSUs does Steven W. King hold after this reported grant?
After the July 10, 2026 grant, Steven W. King holds 250 restricted stock units directly. These RSUs are derivative equity awards that will settle in Series A Convertible Preferred Stock only if the specified performance and service-based vesting conditions are satisfied.
Is any cash consideration involved in Steven W. King’s OTLC RSU grant?
The reported grant price is $0.00 per RSU, indicating no cash payment for the award itself. Value to King depends on future vesting, issuance of Series A Convertible Preferred Stock, and any subsequent conversion into common shares.